VRG Technologies, Inc.


 Home Up Products Patents Investing Press Releases Contacts

  Imaging Antibodies


Vector Research - Global Technologies.


ntibody-based drugs, in particular monoclonal antibody-based products, are on the cusp of significant commercial growth. New developments are spurred in

part by advances in technology that have now surmounted previous technical barriers to commercialization.

According to a soon-to-be-released BUSINESS COMMUNICATIONS CO., INC., study RC-088U Antibody for Therapeutic and Diagnostic Imaging Applications, the total
worldwide market is estimated at nearly $2.8 billion in 1999, and is forecast to grow to almost $9.8 billion in 2004. With the rollout of dozens of new antibody products and expanded indications for existing products expected during the forecast period, the AAGR
(average annual growth rate) for this sector as a whole is projected at 21.8%.

As of August 1999, there were 17 therapeutic and diagnostic monoclonal antibody products on the U.S. market. Worldwide, there were more than 700 monoclonal antibody products in
development by more than 260 companies for the treatment of virtually every debilitating disease. Approximately 220 of these monoclonal antibody products were in clinical trials.
According to the Pharmaceutical Research and Manufacturers of America (PhRMA), monoclonal antibody products represented approximately 37% of all biotechnology products
in development by its members.

Therapeutic applications represent over 99% of the market, and will grow at an average annual rate of 21.6% through the period, thereby growing from $3.6 million in 1999 to $9.7 million in 2004.

Still in its inception stage in the late 90s, diagnostic-imaging applications will grow at a fast AAGR of nearly 50% to reach $196 million by 2004.

This report analyzes and assesses therapeutic and in vivo diagnostic imaging applications of antibodies in human medicine. The document is intended to be comprehensive with respect to products as well as applications. The scope of the study is worldwide and provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development. Included are both polyclonal and monoclonal antibodies. Excluded are therapeutic and diagnostic imaging antibodies for veterinary use. Also excluded are in vitro immunoassay applications of antibodies.

($ Millions)
  1999 2004 AAGR % 
Therapeutic  3,637 9,656 21.6
Diagnostic Imaging 26 196 49.8
Total 3,663 9,852 21.8

RC-088U Antibody for therapeutic and Diagnostic Imaging Applications

Published: December 1999

Data and analysis provided courtesy of BUSINESS COMMUNICATIONS COMPANY, INC., 25 Van Zant Street, Norwalk, CT 06855,  Telephone: (203) 853-4266; ext. 309,  Email: publisher@bccresearch.com

Back Home Up Next 


VRG Technologies, Inc.

Last Modified : 12/10/01 07:09 PM

Copyright 2001